You have 9 free searches left this month | for more free features.

Thrombocytosis

Showing 1 - 25 of 476

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Molecular Biology of Polycythemia and Thrombocytosis

Recruiting
  • Polycythemia
  • Thrombocytosis
    • Salt Lake City, Utah
      University of Utah
    Oct 29, 2021

    Myelodysplastic/Myeloproliferative Tumor With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Tumor,

    Recruiting
    • Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis
    • Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Jan 19, 2022

    Myelofibrosis, Essential Thrombocythemia, MPN Trial in New York (Peptide-based vaccine, Poly ICLC)

    Not yet recruiting
    • Myelofibrosis
    • +2 more
    • Peptide-based vaccine
    • Poly ICLC
    • New York, New York
      Icahn School of Medicine at Mount Sinai
    Jun 7, 2022

    Arterial Function and Atherosclerosis in Essential

    Completed
    • Atherosclerosis
    • imaging
    • (no location specified)
    Oct 6, 2021

    Essential Thrombocythemia Trial (Ropeginterferon alfa-2b-njft (P1101))

    Not yet recruiting
    • Essential Thrombocythemia
    • Ropeginterferon alfa-2b-njft (P1101)
    • (no location specified)
    Jul 28, 2022

    Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF Trial in New York (Canakinumab)

    Recruiting
    • Primary Myelofibrosis
    • +4 more
    • New York, New York
      Ruttenberg Treatment Center
    Jul 18, 2022

    Essential Thrombocytopenia Trial in Tianjin (Recombinant Interferon Alpha, Pegylated interferon alfa-2b)

    Recruiting
    • Essential Thrombocytopenia
    • Recombinant Interferon Alpha
    • Pegylated interferon alfa-2b
    • Tianjin, Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    Jul 18, 2022

    Polycythemia Vera, Essential Thrombocythemia, and

    Not yet recruiting
    • Myeloproliferative Neoplasm
    • Next-generation sequencing
    • (no location specified)
    Jun 27, 2022

    Thrombocythemia, Essential Trial in San Antonio (IMG-7289)

    Recruiting
    • Thrombocythemia, Essential
    • San Antonio, Texas
      Mays Cancer Center
    Dec 14, 2021

    Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Thrombocythemia Myelofibrosis (PET-MF) Trial

    Available
    • Primary Myelofibrosis (PMF)
    • +2 more
    • (no location specified)
    Jan 18, 2022

    Myeloproliferative Tumor, MPN, Essential Thrombocythemia Trial in Orange (N-Acetylcysteine)

    Active, not recruiting
    • Myeloproliferative Neoplasm
    • +4 more
    • Orange, California
      Chao Family Comprehensive Cancer Center, University of Californi
    Jan 20, 2022

    A Prospective, Two-arm, Non-interventional Study of JAKAVI® in

    Active, not recruiting
    • Primary Myelofibrosis
    • +2 more
    • Jakavi
    • Aachen, Germany
      Novartis Investigative Site
    Sep 6, 2021

    Myelofibrosis; Anemia, Anemia, Myelofibrosis Trial in Canton, Gettysburg (DISC-0974)

    Recruiting
    • Myelofibrosis; Anemia
    • +5 more
    • Canton, Ohio
    • +1 more
    Jun 10, 2022

    Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis Trial in Ipoh (NS-018,

    Recruiting
    • Primary Myelofibrosis
    • +2 more
    • Ipoh, Perak, Malaysia
      Hospital Raja Permaisuri Bainun
    Jul 18, 2022

    Myeloproliferative Tumor, Essential Thrombocythemia, Primary Myelofibrosis, Prefibrotic Stage Trial (CALR allele burden

    Not yet recruiting
    • Myeloproliferative Neoplasm
    • +3 more
    • CALR allele burden quantification
    • (no location specified)
    Jun 18, 2021

    Myelofibrosis, Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis Trial in Hangzhou (Jaktinib HCl tablets)

    Recruiting
    • Myelofibrosis
    • +3 more
    • Jaktinib hydrochloride tablets
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital of Medical School of Zhejiang Univ
    Jun 11, 2021

    Myeloproliferative Tumor, Essential Thrombocythemia, JAK2 Mutation Trial in Ottawa (Apixaban 2.5 MG Oral Tablet [ELIQUIS],

    Recruiting
    • Myeloproliferative Neoplasm
    • +5 more
    • Apixaban 2.5 MG Oral Tablet [ELIQUIS]
    • Aspirin 81 mg
    • Ottawa, Ontario, Canada
      The Ottawa Hospital
    Apr 19, 2022

    Essential Thrombocythemia Trial in Tours (Anagrelide, Ruxolitinib (JAKAVI®), IFNa/ PegIFNa)

    Terminated
    • Essential Thrombocythemia
    • Tours, France
      FILO
    Jun 28, 2021

    Primary Myelofibrosis, Myelofibrosis, PMF Trial (MBG453, NIS793, Spartalizumab)

    Withdrawn
    • Primary Myelofibrosis
    • +4 more
    • (no location specified)
    Mar 2, 2021

    Essential Thrombocythaemia Trial in Spain, Sweden, United Kingdom (anagrelide HCl)

    Completed
    • Essential Thrombocythaemia
    • anagrelide hydrochloride
    • Barcelona, Spain
    • +4 more
    Jun 7, 2021

    Myelodysplastic/Myeloproliferative Tumor, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia,

    Recruiting
    • Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Oct 30, 2021

    Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary

    Recruiting
    • Myelofibrosis Transformation in Essential Thrombocythemia
    • +2 more
    • Elotuzumab
    • Questionnaire Administration
    • Houston, Texas
      M D Anderson Cancer Center
    Feb 17, 2021

    Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis

    Recruiting
    • Primary Myelofibrosis (PMF)
    • +2 more
    • Larkspur, California
    • +2 more
    Sep 21, 2021

    Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome Trial in Seattle (Decitabine, Ruxolitinib,

    Recruiting
    • Acute Myeloid Leukemia
    • +8 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Feb 25, 2022